Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

Eli Lilly will expand its manufacturing site in Suzhou China, investing $200 million to produce in-demand drugs Mounjaro and Zepbound.

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...

The newest investment will add 120 new jobs to the plant and brings Lilly’s total investment in the Suzhou site to nearly 15 billion Chinese yuan ($2.1 billion). Lilly isn’t the only drugmaker ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Eli Lilly’s stock surged on the encouraging data. It closed up by 14 percent on Thursday, adding $100 billion to the company’s market value. This was the first of seven main clinical trials of ...

In back-to-back announcements, Eli Lilly said it will invest $200 million to expand its manufacturing site in Suzhou and will open its biotech incubator, known as Lilly Gateway Labs, in China.

US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in Suzhou, Jiangsu province, that will enable it to increase production of ...